Premium
Modulation of associated ovarian carcinoma antigens by 5 cytokines used as single agents or in combination
Author(s) -
ImbertMarcille B. M.,
Thëdrez P.,
SaïMaurel C.,
Francois C.,
Auget J. L.,
Benard J.,
Jacques Y.,
Imai S.,
Chatal J. F.
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910570317
Subject(s) - antigen , cytotoxicity , monoclonal antibody , radioimmunotherapy , flow cytometry , cell culture , interferon gamma , biology , tumor necrosis factor alpha , cytokine , ovarian cancer , cancer research , microbiology and biotechnology , immunology , antibody , medicine , cancer , in vitro , biochemistry , genetics
Optimization of intraperitoneal radioimmunotherapy of ovarian cancer depends on increasing the antigenic expression of tumor cells. For this purpose, we studied the effect of 5 cytokines (IFN‐α, IFN‐β, IFN‐γ, TNF‐α and TGF‐β), used as single agents or in combination, on 4 ovarian cancer cell lines which present different antigenic profiles with the monoclonal antibodies (MAbs) tested (OC125, OVTL‐3, MOv 18 and MOv 19). Analyses were performed by flow cytometry and the Scatchard technique in order to study antigenic modulation. The effect on proliferation was determined by cell counting. Expression of O3 antigen, recognized by the OVTL3 MAb, was increased up to 2.5 times after IFNs and TNF‐α (used as single agent) on the 2 lines presenting low basal expression (SHIN‐3 and IGROVI). The expression of CAI25 antigen and the antigens recognized by MOv 18 and MOv 19 MAbs was not increased by any of the cytokines tested. The combination IFN‐γ + TNF‐α was synergistic on cytotoxicity and enhanced O3 expression, providing 10 times as many sites per cell on the SHIN‐3 line. For 3 other associations (IFN‐α + IFN‐γ, IFN‐β + IFN‐γ and IFN‐α + TNF‐α), there was an additive effect on O3 expression and on cell cytotoxicity. © 1994 Wiley‐Liss, Inc.